

Appendix 4 (as supplied by the authors): Rates of spine, hip and limb fractures from 5 trials*⁺

Site of Fracture		Thiazolidinedione	Control
Spine	Kahn 2006	4 /1456 (0.27%)	3/2895 (0.10%)
	Other trials	No events	No events
Hip/ Femur	Kahn 2006	3/1456 (0.21%)	3/2895 (0.10%)
	Hedblad 2007	0/277 (0%)	1/278 (0.36%)
	AVM 100264	1/294 (0.34%)	1/301 (0.33%)
	Other trials	No events	No events
Unspecified or Other Lower Limb	Kahn 2006	43/1456 (2.95%)	52/2895 (1.80%)
	Jain 2006	0/251 (0%)	2/252 (0.79%)
	Nissen 2008	7/270 (2.59%)	0/273 (0%)
	Other trials	No events	No events
Upper Limb	Kahn 2006	13/1456 (0.89%)	13/2895 (0.45%)
	Hedblad 2007	0/277 (0%)	2/278 (0.72%)
	Nissen 2008	4/270 (1.48%)	0/273 (0%)
	AVM 100264	1/294 (0.34%)	0/301 (0%)
	GSK 49653 351	0/30 (0%)	1/31 (3%)
	Other trials	No events	No events

*Two trials did not specify the exact fracture sites

+Some patients may have had fractures at more than one site